168 related articles for article (PubMed ID: 35781511)
1. Deep Learning for Fully Automated Prediction of Overall Survival in Patients Undergoing Resection for Pancreatic Cancer: A Retrospective Multicenter Study.
Yao J; Cao K; Hou Y; Zhou J; Xia Y; Nogues I; Song Q; Jiang H; Ye X; Lu J; Jin G; Lu H; Xie C; Zhang R; Xiao J; Liu Z; Gao F; Qi Y; Li X; Zheng Y; Lu L; Shi Y; Zhang L
Ann Surg; 2023 Jul; 278(1):e68-e79. PubMed ID: 35781511
[TBL] [Abstract][Full Text] [Related]
2. DeepPrognosis: Preoperative prediction of pancreatic cancer survival and surgical margin via comprehensive understanding of dynamic contrast-enhanced CT imaging and tumor-vascular contact parsing.
Yao J; Shi Y; Cao K; Lu L; Lu J; Song Q; Jin G; Xiao J; Hou Y; Zhang L
Med Image Anal; 2021 Oct; 73():102150. PubMed ID: 34303891
[TBL] [Abstract][Full Text] [Related]
3. Correlation of transcriptional subtypes with a validated CT radiomics score in resectable pancreatic ductal adenocarcinoma.
Salinas-Miranda E; Healy GM; Grünwald B; Jain R; Deniffel D; O'Kane GM; Grant R; Wilson J; Knox J; Gallinger S; Fischer S; Khokha R; Haider MA
Eur Radiol; 2022 Oct; 32(10):6712-6722. PubMed ID: 36006427
[TBL] [Abstract][Full Text] [Related]
4. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of deep learning-derived body composition in advanced pancreatic cancer-a retrospective multicenter study.
Keyl J; Bucher A; Jungmann F; Hosch R; Ziller A; Armbruster R; Malkomes P; Reissig TM; Koitka S; Tzianopoulos I; Keyl P; Kostbade K; Albers D; Markus P; Treckmann J; Nassenstein K; Haubold J; Makowski M; Forsting M; Baba HA; Kasper S; Siveke JT; Nensa F; Schuler M; Kaissis G; Kleesiek J; Braren R
ESMO Open; 2024 Jan; 9(1):102219. PubMed ID: 38194881
[TBL] [Abstract][Full Text] [Related]
6. Validation of Prognostic Radiomic Features From Resectable Pancreatic Ductal Adenocarcinoma in Patients With Advanced Disease Undergoing Chemotherapy.
Salinas-Miranda E; Khalvati F; Namdar K; Deniffel D; Dong X; Abbas E; Wilson JM; O'Kane GM; Knox J; Gallinger S; Haider MA
Can Assoc Radiol J; 2021 Nov; 72(4):605-613. PubMed ID: 33151087
[TBL] [Abstract][Full Text] [Related]
7. Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation.
Healy GM; Salinas-Miranda E; Jain R; Dong X; Deniffel D; Borgida A; Hosni A; Ryan DT; Njeze N; McGuire A; Conlon KC; Dodd JD; Ryan ER; Grant RC; Gallinger S; Haider MA
Eur Radiol; 2022 Apr; 32(4):2492-2505. PubMed ID: 34757450
[TBL] [Abstract][Full Text] [Related]
8. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
Am Surg; 2022 Jun; 88(6):1172-1180. PubMed ID: 33522271
[TBL] [Abstract][Full Text] [Related]
10. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
11. Prognostic stratification in patients with pancreatic ductal adenocarcinoma after curative resection based on preoperative pancreatic contrast-enhanced CT findings.
Li D; Wang L; Cai W; Liang M; Ma X; Zhao X
Eur J Radiol; 2022 Jun; 151():110313. PubMed ID: 35447500
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer.
Murthy P; Zenati MS; Al Abbas AI; Rieser CJ; Bahary N; Lotze MT; Zeh HJ; Zureikat AH; Boone BA
Ann Surg Oncol; 2020 Mar; 27(3):898-906. PubMed ID: 31792715
[TBL] [Abstract][Full Text] [Related]
13. Can we rely on contrast-enhanced CT to identify pancreatic ductal adenocarcinoma? A population-based study in sensitivity and factors associated with false negatives.
LeBlanc M; Kang J; Costa AF
Eur Radiol; 2023 Nov; 33(11):7656-7664. PubMed ID: 37266655
[TBL] [Abstract][Full Text] [Related]
14. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
[TBL] [Abstract][Full Text] [Related]
15. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic adenocarcinoma: quantitative CT features are correlated with fibrous stromal fraction and help predict outcome after resection.
Cai X; Gao F; Qi Y; Lan G; Zhang X; Ji R; Xu Y; Liu C; Shi Y
Eur Radiol; 2020 Sep; 30(9):5158-5169. PubMed ID: 32346792
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Factors in Resected Pancreatic Ductal Adenocarcinoma: Is Neutrophil-Lymphocyte Ratio a Useful Marker?
Merlo I; Ardiles V; Sanchez-Clariá R; Fratantoni E; de Santibañes E; Pekolj J; Mazza O; de Santibañes M
J Gastrointest Cancer; 2023 Jun; 54(2):580-588. PubMed ID: 35653056
[TBL] [Abstract][Full Text] [Related]
19. Preoperative data-based deep learning model for predicting postoperative survival in pancreatic cancer patients.
Lee W; Park HJ; Lee HJ; Jun E; Song KB; Hwang DW; Lee JH; Lim K; Kim N; Lee SS; Byun JH; Kim HJ; Kim SC
Int J Surg; 2022 Sep; 105():106851. PubMed ID: 36049618
[TBL] [Abstract][Full Text] [Related]
20. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
Han Y; Drobisch P; Krüger A; William D; Grützmann K; Böthig L; Polster H; Seifert L; Seifert AM; Distler M; Pecqueux M; Riediger C; Plodeck V; Nebelung H; Weber GF; Pilarsky C; Kahlert U; Hinz U; Roth S; Hackert T; Weitz J; Wong FC; Kahlert C
J Hematol Oncol; 2023 Feb; 16(1):7. PubMed ID: 36737824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
